Anti-ephrin type-A receptor 3 (EphA3) modified TMZ16e loaded nanoparticles (NPs) were found to improve brain targeting efficiency and anti-glioma activity, as well as reverse TMZ resistance (48). This evidence concerns the gene EPHA3 and central nervous system cancer.